NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Development of Patient-Reported Outcome Measures Assessing Tumor-Related Disfigurement and Appearance Concerns in Neurofibromatosis Type 1
Recruiting
- Conditions
- Neurofibromatosis Type 1Neurofibroma
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 110
- Registration Number
- NCT06880991
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Phase 1
Not yet recruiting
- Conditions
- Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT06876142
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Phase 1
Not yet recruiting
- Conditions
- Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT06865664
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
Phase 2
Not yet recruiting
- Conditions
- Recurrent Platinum Resistant Epithelial Ovarian CarcinomaRecurrent Epithelial Endometrial CarcinomaRecurrent Epithelial Cervical Carcinoma
- Interventions
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 95
- Registration Number
- NCT06865677
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Phase 1
Not yet recruiting
- Conditions
- Astrocytoma, IDH-Mutant, Grade 2Recurrent Astrocytoma, IDH-MutantRecurrent Astrocytoma, IDH-Mutant, Grade 3Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Diffuse Midline GliomaRecurrent Glioblastoma, IDH-Wildtype
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT06860594
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Not yet recruiting
- Conditions
- LeukemiaLymphomaHematologic Malignancy
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT06856226
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin
Phase 1
Not yet recruiting
- Conditions
- Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Imaging Procedure
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 92
- Registration Number
- NCT06811116
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
Phase 1
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Radiation: Actinium Ac 225 LintuzumabProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT06802523
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Phase 2
Recruiting
- Conditions
- Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 160
- Registration Number
- NCT06770582
- Locations
- 🇺🇸
Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States
🇺🇸Helen F Graham Cancer Center, Newark, Delaware, United States
🇺🇸Medical Oncology Hematology Consultants PA, Newark, Delaware, United States
Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia
Recruiting
- Conditions
- Fanconi Anemia
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT06744283
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath